mavii

New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into force in February next year. Patient involvement is key, they say.

The lay summary text is below. After reading this ... which can lead to more personalised treatment. For example, these biomarkers will enable doctors to identify patients who will have the greatest success of responding to the combination.